Low-Dose Radiation Brachytherapy Market Size, Share & Trend Analysis - Global - 2025-2031 - Includes: LDR Needle Market and LDR Brachytherapy Iodine Seed Market
Description
Global Low-Dose Radiation Brachytherapy Market Report, 2025 Edition
Executive Summary
The global low-dose radiation brachytherapy (LDRB) market was valued at $102 million in 2024. The market is expected to grow at a 2.2 percent CAGR to reach $119 million by 2032. While growth is moderate compared to some other oncology segments, LDR brachytherapy remains a vital component of prostate cancer treatment and a targeted option for selected tumors in other anatomical sites.
This report covers the complete device spectrum for LDR brachytherapy, including LDR needles and iodine-125 radioactive seeds. In LDRB, thin needles are inserted through the perineum and permanently implanted radioactive seeds are placed within the prostate. Fluoroscopy and ultrasound are used to visualize the gland and guide accurate implant placement. I-125 seeds are also indicated for a range of superficial and deep-seated tumors, including select lung, pancreas, head and neck, intrathoracic, intra-abdominal, and superficial lesions.
The market is driven by the incidence and recurrence of prostate cancer. In 2020, there were an estimated 1.4 million new prostate cancer cases globally, and the proportion of patients eligible for localized treatment continues to grow. Cancer recurrence and prolonged survival also sustain ongoing demand for targeted therapies such as brachytherapy.
This edition quantifies unit sales, average selling prices, market values, and competitor shares. It reviews clinical drivers, pricing dynamics, competitive strategies, and technology trends, and provides forecasts to 2032 based on disease incidence, procedure adoption, and reimbursement patterns.
Market Overview
Low-dose radiation brachytherapy is a form of internal radiation treatment that delivers radiation directly to or near the tumor. In the context of this report, LDR brachytherapy is focused primarily on permanent seed implantation, especially for prostate cancer. Seeds remain in the body and continuously emit low levels of radiation over time, gradually damaging tumor cell DNA and leading to local control.
The LDRB procedure typically involves:
Transperineal needle insertion guided by transrectal ultrasound and fluoroscopy
Precise placement of iodine-125 radioactive seeds within or around the tumor volume
Post-implant dosimetry to confirm coverage and assess dose distribution
LDRB offers several treatment advantages:
Highly localized dose delivery
Potential sparing of surrounding tissues compared to external beam radiotherapy
Single procedure treatment versus multiple sessions
Shorter overall treatment time for many patients
The market analyzed in this report includes:
LDR needles used for implantation procedures
Iodine-125 seeds used as permanent implants
Although other isotopes exist in radiotherapy, this analysis is focused on I-125 within the LDR brachytherapy device space, in line with the defined scope.
Prostate cancer is the primary clinical indication. However, I-125 seeds are also indicated for certain superficial and intrathoracic lesions, intra-abdominal tumors, lung lesions, pancreatic lesions, and head and neck tumors, particularly in specialty centers with brachytherapy expertise.
The overall LDRB market is shaped by:
Prostate cancer epidemiology
Evolving treatment options, including surgery and external beam radiotherapy
Recurrence rates and salvage therapy patterns
Physician familiarity and institutional expertise
Reimbursement and cost-effectiveness considerations
Although newer radiotherapy methods, such as advanced external beam and high-dose-rate (HDR) brachytherapy, compete for the same patient pool, LDRB remains an important modality, especially in centers with established programs.
Market Drivers
Increasing Rates of Cancer
Cancer incidence continues to rise as populations age and diagnostic capabilities improve. Prostate cancer is one of the most commonly diagnosed malignancies in men. It is projected that prostate cancer incidence will exceed 10 percent of male cancer cases by 2025 in many regions.
In 2020, there were more than 1.4 million new cases of prostate cancer worldwide. This expanding patient base supports a stable pool of candidates for localized treatments, including LDR brachytherapy. As screening and early detection improve, the number of patients presenting with localized or locally advanced disease remains high, which sustains procedure volumes.
Recurrence of Prostate Cancer
Cancer recurrence is an important driver for LDRB. Factors contributing to recurrence include:
Longer life expectancy, which provides more time for recurrent disease to develop
Shifts in treatment patterns toward gland-preserving or focal therapies
Patients who initially receive treatments that can leave behind residual or microscopic disease
When recurrence occurs in the prostate or surrounding tissues, salvage brachytherapy can be considered in selected cases. This incremental demand supports additional procedures over a patient’s lifetime. The recurrence of prostate cancer, combined with the desire to preserve quality of life and organ function, increases the relevance of localized options such as LDRB.
Enhanced Tumor Specificity and Targeted Therapy
LDR brachytherapy offers high tumor specificity compared with external beam radiotherapy. By placing radioactive sources directly into or adjacent to the tumor, physicians can:
Deliver higher doses to the tumor while limiting exposure to surrounding tissues
Tailor seed locations and dose distributions to the patient’s anatomy
Achieve sustained dose delivery over time through permanent seed implants
This localized approach can be particularly beneficial for men who are not candidates for radical prostatectomy due to age, comorbidities, or personal preference. It can also be an option for patients who may be unable to complete extended external beam courses of up to eight weeks.
As payers and providers continue to evaluate the balance between tumor control, toxicity, and resource use, LDR brachytherapy’s targeted nature remains a key driver of its continued adoption.
Market Limiters
Procedural Side Effects
Despite its advantages, LDR brachytherapy has well-known side effects. Post-implant complications can include:
Hematuria (blood in the urine)
Hematospermia (blood in the ejaculate)
Rectal bleeding or blood in the stool
Urinary urgency, frequency, and discomfort
Over the long term, the risk of erectile dysfunction can be similar to that observed after external beam radiotherapy. These side effects are a concern for both patients and clinicians. Some patients may choose alternative treatments, such as external beam radiotherapy or surgery, based on their expectations and perceived risks.
Patient awareness of side effects, as well as physician communication about risks, influences procedure acceptance and overall brachytherapy demand.
Price Competition in the Brachytherapy Seed Market
The brachytherapy seed market is highly competitive. New technologies in prostate cancer treatment, including advanced external beam modalities and surgical techniques, compete directly for the same patient pool. If these modalities offer similar clinical outcomes at comparable or lower cost, they can limit LDR seed market growth.
Because the effectiveness of brachytherapy is often comparable to other established prostate cancer treatments, pricing pressure is persistent. Seed manufacturers must keep device prices competitive, which constrains revenue growth even when unit volumes are stable. Hospitals also evaluate the total cost of treatment, including seed procurement, procedural time, and imaging resources, which creates an environment of continual cost optimization.
Procedural Limitations
LDR brachytherapy is primarily appropriate for localized disease. It is not considered a stand-alone option when cancer has spread beyond the prostate capsule. In such cases, brachytherapy may be used at a lower dose as part of a combined regimen with external beam radiotherapy.
These clinical limitations reduce the eligible patient pool for LDRB. Advancing disease at presentation, patient comorbidities, and tumor extent all influence whether LDRB is selected. As treatment guidelines and staging approaches evolve, the role of LDRB must fit into broader multidisciplinary treatment pathways, which can limit procedural growth in some regions.
Market Coverage and Data Scope
Quantitative Coverage
Market size and value
Market shares for leading competitors
Market forecasts through 2032
Growth rates by segment
Units sold by device type
Average selling prices (ASPs)
Qualitative Coverage
Market growth trends and clinical adoption patterns
Market limiters and competitive challenges
Company profiles and product portfolio reviews
SWOT insights for leading competitors
Recent mergers and acquisitions
Regulatory considerations and device approvals
Disease overviews and treatment pathways relevant to brachytherapy
Data Sources
Primary interviews with radiation oncologists, urologists, and industry executives
Government and cancer registry data on prostate cancer incidence
Regulatory filings and device databases
Hospital procurement and utilization information
Import and export data for brachytherapy devices
iData Research’s internal market models and validation frameworks
Markets Covered and Segmentation
Global Low-Dose Radiation Brachytherapy Device Market
By Device Type
LDR needles
Needles used for transperineal implantation of radioactive seeds
LDR brachytherapy iodine seeds (I-125)
Permanent radioactive seeds indicated for:
Prostate cancer
Superficial lesions
Intrathoracic lesions
Intra-abdominal tumors
Lung tumors
Pancreatic lesions
Head and neck tumors
Each device category is analyzed in terms of units, ASPs, and revenue across major global regions.
Competitive Analysis
Becton Dickinson (BD)
Becton Dickinson was the leading competitor in the global LDRB market in 2024. The company offers BrachySource iodine seeds, which are well established in prostate brachytherapy and other indicated tumor types. BD’s strong distribution network, brand recognition, and presence across a broad range of medical devices support its leadership position.
By leveraging its existing relationships with hospitals, cancer centers, and radiation oncology departments, BD maintains a solid installed base and consistent seed usage. Its emphasis on quality, reliability, and supply continuity is an important differentiator in a field where treatment schedules and radiation handling require highly dependable product availability.
Theragenics
Theragenics ranked as the second-leading competitor in the LDRB market in 2024. The company specializes in radioactive seeds and offers both palladium and iodine solutions, as well as LDR needles. This focused brachytherapy portfolio positions Theragenics as a dedicated partner to radiation oncologists and urologists.
Theragenics’ products are distributed in Europe by BXTAccelyon, which helps extend reach beyond its core markets. The company’s specialization in permanent seed implants and associated delivery tools supports its continued relevance in centers that maintain active brachytherapy programs.
Eckert & Ziegler BEBIG
Eckert & Ziegler BEBIG was the third-leading competitor in the LDR brachytherapy market in 2024. The company offers the IsoSeed line of brachytherapy seeds and has long-standing expertise in medical radioisotopes and radiation technologies.
With a portfolio that includes seeds for multiple tumor indications and a global footprint, Eckert & Ziegler BEBIG is a significant player in regions where brachytherapy remains a standard part of prostate cancer treatment. Its capabilities in isotope manufacturing and radiopharmaceutical logistics underpin its competitive position.
Technology and Practice Trends
Continued use of I-125 seeds as a standard for permanent prostate implants
Stable procedural role for LDRB in localized prostate cancer within selected centers
Evaluation of combination therapies that integrate LDRB with external beam radiotherapy for more advanced or high-risk cases
Emphasis on precise imaging and treatment planning to optimize dose distribution and minimize toxicity
Use of updated planning software and imaging techniques to better tailor seed placement
Interest in comparative outcome studies between LDRB, external beam radiotherapy, HDR brachytherapy, and prostatectomy
Increased focus on patient-reported outcomes and quality of life measures when selecting treatment modalities
While radical prostatectomy and external beam techniques continue to evolve, LDRB remains an important option for suitable patients, particularly in facilities with established brachytherapy workflows and experience.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
The Global Low-Dose Radiation Brachytherapy Market Report helps stakeholders answer key strategic questions, including:
How large is the current global LDRB market, and what is the realistic growth outlook through 2032
How do cancer incidence trends and prostate cancer recurrence patterns influence procedure volumes
How does LDR brachytherapy compare with other prostate cancer treatments in terms of adoption and cost pressure
Which regions are maintaining or expanding LDRB capacity, and where is demand more stable or declining
Which companies lead the LDR needle and I-125 seed markets, and how are they differentiated
How do pricing, competition, and reimbursement impact margins and investment decisions
How should manufacturers position products in a competitive environment that includes surgery, external beam radiotherapy, and alternative radiotherapy modalities
Use this report to quantify demand, refine product strategy, prioritize geographies, and align sales and marketing planning with long term clinical and economic trends in prostate cancer treatment.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Executive Summary
The global low-dose radiation brachytherapy (LDRB) market was valued at $102 million in 2024. The market is expected to grow at a 2.2 percent CAGR to reach $119 million by 2032. While growth is moderate compared to some other oncology segments, LDR brachytherapy remains a vital component of prostate cancer treatment and a targeted option for selected tumors in other anatomical sites.
This report covers the complete device spectrum for LDR brachytherapy, including LDR needles and iodine-125 radioactive seeds. In LDRB, thin needles are inserted through the perineum and permanently implanted radioactive seeds are placed within the prostate. Fluoroscopy and ultrasound are used to visualize the gland and guide accurate implant placement. I-125 seeds are also indicated for a range of superficial and deep-seated tumors, including select lung, pancreas, head and neck, intrathoracic, intra-abdominal, and superficial lesions.
The market is driven by the incidence and recurrence of prostate cancer. In 2020, there were an estimated 1.4 million new prostate cancer cases globally, and the proportion of patients eligible for localized treatment continues to grow. Cancer recurrence and prolonged survival also sustain ongoing demand for targeted therapies such as brachytherapy.
This edition quantifies unit sales, average selling prices, market values, and competitor shares. It reviews clinical drivers, pricing dynamics, competitive strategies, and technology trends, and provides forecasts to 2032 based on disease incidence, procedure adoption, and reimbursement patterns.
Market Overview
Low-dose radiation brachytherapy is a form of internal radiation treatment that delivers radiation directly to or near the tumor. In the context of this report, LDR brachytherapy is focused primarily on permanent seed implantation, especially for prostate cancer. Seeds remain in the body and continuously emit low levels of radiation over time, gradually damaging tumor cell DNA and leading to local control.
The LDRB procedure typically involves:
Transperineal needle insertion guided by transrectal ultrasound and fluoroscopy
Precise placement of iodine-125 radioactive seeds within or around the tumor volume
Post-implant dosimetry to confirm coverage and assess dose distribution
LDRB offers several treatment advantages:
Highly localized dose delivery
Potential sparing of surrounding tissues compared to external beam radiotherapy
Single procedure treatment versus multiple sessions
Shorter overall treatment time for many patients
The market analyzed in this report includes:
LDR needles used for implantation procedures
Iodine-125 seeds used as permanent implants
Although other isotopes exist in radiotherapy, this analysis is focused on I-125 within the LDR brachytherapy device space, in line with the defined scope.
Prostate cancer is the primary clinical indication. However, I-125 seeds are also indicated for certain superficial and intrathoracic lesions, intra-abdominal tumors, lung lesions, pancreatic lesions, and head and neck tumors, particularly in specialty centers with brachytherapy expertise.
The overall LDRB market is shaped by:
Prostate cancer epidemiology
Evolving treatment options, including surgery and external beam radiotherapy
Recurrence rates and salvage therapy patterns
Physician familiarity and institutional expertise
Reimbursement and cost-effectiveness considerations
Although newer radiotherapy methods, such as advanced external beam and high-dose-rate (HDR) brachytherapy, compete for the same patient pool, LDRB remains an important modality, especially in centers with established programs.
Market Drivers
Increasing Rates of Cancer
Cancer incidence continues to rise as populations age and diagnostic capabilities improve. Prostate cancer is one of the most commonly diagnosed malignancies in men. It is projected that prostate cancer incidence will exceed 10 percent of male cancer cases by 2025 in many regions.
In 2020, there were more than 1.4 million new cases of prostate cancer worldwide. This expanding patient base supports a stable pool of candidates for localized treatments, including LDR brachytherapy. As screening and early detection improve, the number of patients presenting with localized or locally advanced disease remains high, which sustains procedure volumes.
Recurrence of Prostate Cancer
Cancer recurrence is an important driver for LDRB. Factors contributing to recurrence include:
Longer life expectancy, which provides more time for recurrent disease to develop
Shifts in treatment patterns toward gland-preserving or focal therapies
Patients who initially receive treatments that can leave behind residual or microscopic disease
When recurrence occurs in the prostate or surrounding tissues, salvage brachytherapy can be considered in selected cases. This incremental demand supports additional procedures over a patient’s lifetime. The recurrence of prostate cancer, combined with the desire to preserve quality of life and organ function, increases the relevance of localized options such as LDRB.
Enhanced Tumor Specificity and Targeted Therapy
LDR brachytherapy offers high tumor specificity compared with external beam radiotherapy. By placing radioactive sources directly into or adjacent to the tumor, physicians can:
Deliver higher doses to the tumor while limiting exposure to surrounding tissues
Tailor seed locations and dose distributions to the patient’s anatomy
Achieve sustained dose delivery over time through permanent seed implants
This localized approach can be particularly beneficial for men who are not candidates for radical prostatectomy due to age, comorbidities, or personal preference. It can also be an option for patients who may be unable to complete extended external beam courses of up to eight weeks.
As payers and providers continue to evaluate the balance between tumor control, toxicity, and resource use, LDR brachytherapy’s targeted nature remains a key driver of its continued adoption.
Market Limiters
Procedural Side Effects
Despite its advantages, LDR brachytherapy has well-known side effects. Post-implant complications can include:
Hematuria (blood in the urine)
Hematospermia (blood in the ejaculate)
Rectal bleeding or blood in the stool
Urinary urgency, frequency, and discomfort
Over the long term, the risk of erectile dysfunction can be similar to that observed after external beam radiotherapy. These side effects are a concern for both patients and clinicians. Some patients may choose alternative treatments, such as external beam radiotherapy or surgery, based on their expectations and perceived risks.
Patient awareness of side effects, as well as physician communication about risks, influences procedure acceptance and overall brachytherapy demand.
Price Competition in the Brachytherapy Seed Market
The brachytherapy seed market is highly competitive. New technologies in prostate cancer treatment, including advanced external beam modalities and surgical techniques, compete directly for the same patient pool. If these modalities offer similar clinical outcomes at comparable or lower cost, they can limit LDR seed market growth.
Because the effectiveness of brachytherapy is often comparable to other established prostate cancer treatments, pricing pressure is persistent. Seed manufacturers must keep device prices competitive, which constrains revenue growth even when unit volumes are stable. Hospitals also evaluate the total cost of treatment, including seed procurement, procedural time, and imaging resources, which creates an environment of continual cost optimization.
Procedural Limitations
LDR brachytherapy is primarily appropriate for localized disease. It is not considered a stand-alone option when cancer has spread beyond the prostate capsule. In such cases, brachytherapy may be used at a lower dose as part of a combined regimen with external beam radiotherapy.
These clinical limitations reduce the eligible patient pool for LDRB. Advancing disease at presentation, patient comorbidities, and tumor extent all influence whether LDRB is selected. As treatment guidelines and staging approaches evolve, the role of LDRB must fit into broader multidisciplinary treatment pathways, which can limit procedural growth in some regions.
Market Coverage and Data Scope
Quantitative Coverage
Market size and value
Market shares for leading competitors
Market forecasts through 2032
Growth rates by segment
Units sold by device type
Average selling prices (ASPs)
Qualitative Coverage
Market growth trends and clinical adoption patterns
Market limiters and competitive challenges
Company profiles and product portfolio reviews
SWOT insights for leading competitors
Recent mergers and acquisitions
Regulatory considerations and device approvals
Disease overviews and treatment pathways relevant to brachytherapy
Data Sources
Primary interviews with radiation oncologists, urologists, and industry executives
Government and cancer registry data on prostate cancer incidence
Regulatory filings and device databases
Hospital procurement and utilization information
Import and export data for brachytherapy devices
iData Research’s internal market models and validation frameworks
Markets Covered and Segmentation
Global Low-Dose Radiation Brachytherapy Device Market
By Device Type
LDR needles
Needles used for transperineal implantation of radioactive seeds
LDR brachytherapy iodine seeds (I-125)
Permanent radioactive seeds indicated for:
Prostate cancer
Superficial lesions
Intrathoracic lesions
Intra-abdominal tumors
Lung tumors
Pancreatic lesions
Head and neck tumors
Each device category is analyzed in terms of units, ASPs, and revenue across major global regions.
Competitive Analysis
Becton Dickinson (BD)
Becton Dickinson was the leading competitor in the global LDRB market in 2024. The company offers BrachySource iodine seeds, which are well established in prostate brachytherapy and other indicated tumor types. BD’s strong distribution network, brand recognition, and presence across a broad range of medical devices support its leadership position.
By leveraging its existing relationships with hospitals, cancer centers, and radiation oncology departments, BD maintains a solid installed base and consistent seed usage. Its emphasis on quality, reliability, and supply continuity is an important differentiator in a field where treatment schedules and radiation handling require highly dependable product availability.
Theragenics
Theragenics ranked as the second-leading competitor in the LDRB market in 2024. The company specializes in radioactive seeds and offers both palladium and iodine solutions, as well as LDR needles. This focused brachytherapy portfolio positions Theragenics as a dedicated partner to radiation oncologists and urologists.
Theragenics’ products are distributed in Europe by BXTAccelyon, which helps extend reach beyond its core markets. The company’s specialization in permanent seed implants and associated delivery tools supports its continued relevance in centers that maintain active brachytherapy programs.
Eckert & Ziegler BEBIG
Eckert & Ziegler BEBIG was the third-leading competitor in the LDR brachytherapy market in 2024. The company offers the IsoSeed line of brachytherapy seeds and has long-standing expertise in medical radioisotopes and radiation technologies.
With a portfolio that includes seeds for multiple tumor indications and a global footprint, Eckert & Ziegler BEBIG is a significant player in regions where brachytherapy remains a standard part of prostate cancer treatment. Its capabilities in isotope manufacturing and radiopharmaceutical logistics underpin its competitive position.
Technology and Practice Trends
Continued use of I-125 seeds as a standard for permanent prostate implants
Stable procedural role for LDRB in localized prostate cancer within selected centers
Evaluation of combination therapies that integrate LDRB with external beam radiotherapy for more advanced or high-risk cases
Emphasis on precise imaging and treatment planning to optimize dose distribution and minimize toxicity
Use of updated planning software and imaging techniques to better tailor seed placement
Interest in comparative outcome studies between LDRB, external beam radiotherapy, HDR brachytherapy, and prostatectomy
Increased focus on patient-reported outcomes and quality of life measures when selecting treatment modalities
While radical prostatectomy and external beam techniques continue to evolve, LDRB remains an important option for suitable patients, particularly in facilities with established brachytherapy workflows and experience.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
The Global Low-Dose Radiation Brachytherapy Market Report helps stakeholders answer key strategic questions, including:
How large is the current global LDRB market, and what is the realistic growth outlook through 2032
How do cancer incidence trends and prostate cancer recurrence patterns influence procedure volumes
How does LDR brachytherapy compare with other prostate cancer treatments in terms of adoption and cost pressure
Which regions are maintaining or expanding LDRB capacity, and where is demand more stable or declining
Which companies lead the LDR needle and I-125 seed markets, and how are they differentiated
How do pricing, competition, and reimbursement impact margins and investment decisions
How should manufacturers position products in a competitive environment that includes surgery, external beam radiotherapy, and alternative radiotherapy modalities
Use this report to quantify demand, refine product strategy, prioritize geographies, and align sales and marketing planning with long term clinical and economic trends in prostate cancer treatment.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Table of Contents
204 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
